We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the medicines.ie website. Find out more

Roche Products (Ireland) Ltd

3004 Lake Drive, Citywest, Naas Road, Dublin 24,
Telephone: +353 1 469 0700
Fax: +353 1 469 0791
Medical Information e-mail: ireland.druginfo@roche.com
Patient Information Leaflet last updated on medicines.ie: 18/12/2017
PIL Perjeta 420 mg Concentrate for Solution for Infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 18/12/2017 and displayed until Current
Reasons for adding or updating:
  • Change to section 4 - possible side effects
  • Removal of black triangle
  • Change to section 2 - what you need to know - warnings and precautions
Updated on 17/08/2017 and displayed until 18/12/2017
Reasons for adding or updating:
  • Change to Section 1 - what the product is
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 6 - date of revision
Updated on 23/09/2015 and displayed until 17/08/2017
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to date of revision
Updated on 03/08/2015 and displayed until 23/09/2015
Reasons for adding or updating:
  • Change to, or new use for medicine
  • Change to instructions about missed dose
  • Change to side-effects
  • Change to date of revision
  • Change to dosage and administration
  • Changes to therapeutic indications
Updated on 22/04/2015 and displayed until 03/08/2015
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to date of revision
Updated on 01/08/2014 and displayed until 22/04/2015
Reasons for adding or updating:
  • Addition of information on reporting a side effect.
Updated on 20/09/2013 and displayed until 01/08/2014
Reasons for adding or updating:
  • Addition of information on reporting a side effect.
Updated on 07/03/2013 and displayed until 20/09/2013
Reasons for adding or updating:
  • New PIL for new product

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Pertuzumab